新的热拉西兰药物将高Lp(a)水平削减80%,有可能帮助心脏病患者。 New drug zerlasiran cuts high Lp(a) levels by 80%, potentially aiding heart disease patients.

一项新的研究表明,针对高脂蛋白(a)(Lp(a))的药物zerlasiran可以将心血管疾病患者的Lp(a)水平降低80%以上,其影响长达60周。 A new study shows that zerlasiran, a drug targeting high lipoprotein(a) (Lp(a)), can reduce Lp(a) levels by over 80% in patients with cardiovascular disease, with effects lasting up to 60 weeks. 第2阶段试验涉及178名病人,发现该药物安全,具有注射现场反应等轻微副作用。 The phase 2 trial, involving 178 patients, found the drug safe with mild side effects like injection site reactions. 这些调查结果表明,对Lp(a)水平高的人来说,zerlasiran可能是一种新的治疗方案,这是一个与心血管疾病风险增加有关的因素。 These findings suggest zerlasiran could be a new treatment option for those with high Lp(a) levels, a factor linked to increased cardiovascular disease risk.